CA2268175A1 - Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery - Google Patents

Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery

Info

Publication number
CA2268175A1
CA2268175A1 CA002268175A CA2268175A CA2268175A1 CA 2268175 A1 CA2268175 A1 CA 2268175A1 CA 002268175 A CA002268175 A CA 002268175A CA 2268175 A CA2268175 A CA 2268175A CA 2268175 A1 CA2268175 A1 CA 2268175A1
Authority
CA
Canada
Prior art keywords
enteric polymer
coating layer
colon
dosage form
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002268175A
Other languages
French (fr)
Other versions
CA2268175C (en
Inventor
Gary Robert Kelm
Koji Kondo
Akio Nakajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
The Procter & Gamble Company
Gary Robert Kelm
Koji Kondo
Akio Nakajima
Procter & Gamble Far East Inc.
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company, Gary Robert Kelm, Koji Kondo, Akio Nakajima, Procter & Gamble Far East Inc., Mayo Foundation For Medical Education And Research filed Critical The Procter & Gamble Company
Publication of CA2268175A1 publication Critical patent/CA2268175A1/en
Application granted granted Critical
Publication of CA2268175C publication Critical patent/CA2268175C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising: a) a safe and effective amount of a therapeutically active agent incorporated into a compressed, bi-convex tablet, with a maximum diameter of about 4 mm to about 10 mm; b) a non-pH
dependent smoothing coat applied to the tablet to provide a smooth tablet surface free from edges or sharp curves; and c) an enteric polymer coating material comprising at least one inner coating layer and only one outer coating layer; wherein the therapeutically active agent is released at a point near the inlet to, or within the colon;
each of the inner coating layer(s) is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 5 to about 6.3;
and the outer coating layer is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 6.8 to about 7.2.
CA002268175A 1996-10-11 1997-10-10 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery Expired - Fee Related CA2268175C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/728,946 1996-10-11
US08/728,946 US5914132A (en) 1993-02-26 1996-10-11 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
PCT/US1997/018564 WO1998016206A1 (en) 1996-10-11 1997-10-10 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery

Publications (2)

Publication Number Publication Date
CA2268175A1 true CA2268175A1 (en) 1998-04-23
CA2268175C CA2268175C (en) 2002-04-23

Family

ID=24928914

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268175A Expired - Fee Related CA2268175C (en) 1996-10-11 1997-10-10 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery

Country Status (9)

Country Link
US (1) US5914132A (en)
EP (1) EP0932396B1 (en)
JP (1) JP4276299B2 (en)
CN (1) CN1101675C (en)
AT (1) ATE234079T1 (en)
BR (1) BR9712292A (en)
CA (1) CA2268175C (en)
DE (1) DE69719774T2 (en)
WO (1) WO1998016206A1 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
MXPA01007024A (en) 1999-01-08 2002-03-27 B Bacaner Marvin Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions.
US7138143B1 (en) 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
HU230402B1 (en) * 2000-02-10 2016-04-28 Evonik Röhm Gmbh Acrylic enteric coating compositions
CZ299591B6 (en) * 2000-06-23 2008-09-10 Bioprojet Dry powder pharmaceutical composition, suitable for oral administration
IT1318625B1 (en) 2000-07-14 2003-08-27 Roberto Valducci ORAL SOLID PHARMACEUTICAL FORMULATIONS WITH MULTI-PHASE RELEASE - EMPLOYEE.
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
WO2002092003A2 (en) * 2001-05-11 2002-11-21 Bacaner Marvin B Novel therapeutical quaternary ammonium compositions
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
AU2005221457B2 (en) * 2004-03-10 2010-08-12 Taisho Pharmaceutical Co., Ltd. Poorly water-soluble drug-containing solid formulation
PL1750862T3 (en) 2004-06-04 2011-06-30 Teva Pharma Pharmaceutical composition containing irbesartan
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060147394A1 (en) 2004-12-30 2006-07-06 Ramachandra Shastry Tooth whitening composition containing cross-linked polymer-peroxides
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
DK1889198T3 (en) 2005-04-28 2015-02-09 Proteus Digital Health Inc Pharma-informatics system
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
RU2009101309A (en) * 2006-06-19 2010-07-27 МакНЕЙЛ-ППС, ИНК. (US) PARTICULAR COATED PARTICLES CONTAINING AN ACTIVE INGREDIENT
ES2400964T3 (en) 2007-04-04 2013-04-15 Sigmoid Pharma Limited Pharmaceutical compositions of cyclosporine
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090074944A1 (en) * 2007-09-18 2009-03-19 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090136650A1 (en) * 2007-09-18 2009-05-28 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
AR071706A1 (en) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd A PHARMACEUTICAL FORMULATION OF CILOSTAZOL SOLIDA OF SUSTAINED LIBERATION AND METHOD OF PREPARATION.
MY161146A (en) 2009-04-28 2017-04-14 Proteus Digital Health Inc Highly-reliable ingestible event markers and methods for using the same
CN102470106B (en) 2009-05-18 2015-09-23 希格默伊德药业有限公司 Comprise the compositions of oil droplet
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
AR077420A1 (en) 2009-07-22 2011-08-24 Gruenenthal Gmbh DOSAGE METHOD RESISTANT TO HANDLING FOR OXIDATION SENSITIVE OPTIONS
IN2012DN00781A (en) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
CA2795746C (en) 2010-04-07 2019-10-01 Timothy Robertson Miniature ingestible device
ES2486791T3 (en) 2010-09-02 2014-08-19 Grünenthal GmbH Tamper resistant dosage form comprising an inorganic salt
JP2014504902A (en) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス, インコーポレイテッド Ingestible device with medicinal product
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
RS56527B1 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
LT2736495T (en) 2011-07-29 2017-11-10 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
CN102319218B (en) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 Drug sustained and controlled release microparticle preparation for treating intestinal diseases, and preparation method thereof
US10588857B2 (en) * 2012-03-29 2020-03-17 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
RS56839B1 (en) * 2012-04-30 2018-04-30 Tillotts Pharma Ag A delayed release drug formulation
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
KR102008417B1 (en) * 2012-12-04 2019-08-08 롯데정밀화학 주식회사 Laminated film and film laminating method
JP2016508529A (en) 2013-01-29 2016-03-22 プロテウス デジタル ヘルス, インコーポレイテッド Highly expandable polymer film and composition containing the same
MX369967B (en) 2013-02-22 2019-11-27 Zeria Pharm Co Ltd Enteric coated tablet.
EP2953619A1 (en) 2013-03-15 2015-12-16 Warner Chilcott Company, LLC Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
JP5941240B2 (en) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス, インコーポレイテッド Metal detector device, system and method
MX371432B (en) 2013-05-29 2020-01-30 Gruenenthal Gmbh Tamper-resistant dosage form containing one or more particles.
MX368846B (en) 2013-07-12 2019-10-18 Gruenenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer.
EP3024447A1 (en) * 2013-07-24 2016-06-01 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
CA2920533A1 (en) * 2013-08-06 2015-02-12 Tasly Pharmaceutical Group Co., Ltd.. Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
KR102237356B1 (en) * 2013-10-29 2021-04-08 틸로츠 파마 아게 A delayed release drug formulation
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
CN106176619B (en) * 2014-08-06 2020-10-16 天士力医药集团股份有限公司 Andrographolide enteric-coated pellet positioning preparation
ES2858517T3 (en) 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Compositions comprising cyclosporin
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
KR20180080189A (en) 2015-09-01 2018-07-11 퍼스트 웨이브 바이오, 인코포레이티드 And compositions for treating diseases associated with abnormal inflammatory response
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
SG11201900511VA (en) 2016-07-22 2019-02-27 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers
CA3041041A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
EP3662902A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
KR102584268B1 (en) * 2020-04-22 2023-10-05 영진약품 주식회사 Formulation comprising pirfenidone with improved drug safety and stability and method for the preparing the same
CN115192535B (en) * 2022-06-23 2023-08-29 广东逸舒制药股份有限公司 Aminometacin enteric-coated tablet and preparation method thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764590A (en) * 1952-03-17 1956-09-25 Thomae Gmbh Dr K Certain 4, 4'-disubstituted-diphenylpyridyl methanes and process
DE1204363B (en) * 1963-09-10 1965-11-04 Hoffmann La Roche Process for the production of an oral medicinal preparation which only releases its active ingredient in the ileum
LU72439A1 (en) * 1975-05-09 1977-02-09
JPS53133625A (en) * 1977-04-25 1978-11-21 Shin Etsu Chem Co Ltd Manufacturing of pharmaceutical coated with enteric film
IT1115596B (en) * 1978-03-13 1986-02-03 Bayer Italia Spa METHOD FOR THE PREPARATION OF GASTORESISTANT AND ENTERO-SOLUBLE MICROGRANULES OF PHARMACEUTICAL SUBSTANCES, IN PARTICULAR OF PROTEIN SUBSTANCES AND MICROGRANULES PREPARED WITH THE METHOD
FR2471186A1 (en) * 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
SE8003805L (en) * 1980-05-21 1981-11-22 Haessle Ab A PHARMACEUTICAL PREPARATION WITH IMPROVED EMISSION PROPERTY
JPS5799521A (en) * 1980-12-11 1982-06-21 Eisai Co Ltd Solid composition containing bisacodyl
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
JPS59139317A (en) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk Prolonged release "nifedipine(r)" pharmaceutical
JPS59193816A (en) * 1983-04-19 1984-11-02 Morishita Jintan Kk Preparation of enteric soft capsule
FR2556965B1 (en) * 1983-12-21 1986-08-22 Rhone Poulenc Sante NEW GALENIC FORM OF CONTROLLED RELEASE KETOPROFEN
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61221117A (en) * 1985-03-26 1986-10-01 Fujisawa Pharmaceut Co Ltd Enteric hard capsule
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4822629A (en) * 1986-12-12 1989-04-18 Norwich Eaton Pharmaceuticals, Inc. Azumolene dosage form
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
JPS63258815A (en) * 1987-04-16 1988-10-26 Kiyuushin Seiyaku Kk Bisacodyl-containing solid composition
EP0313845A1 (en) * 1987-09-29 1989-05-03 Warner-Lambert Company Stabilization of enteric coated dosage form
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
JPH089536B2 (en) * 1987-10-30 1996-01-31 日清製粉株式会社 Method for producing enteric coated capsule
IT1230576B (en) * 1988-10-20 1991-10-28 Angeli Inst Spa ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON
SE8903914D0 (en) * 1989-11-22 1989-11-22 Draco Ab ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
IT1246382B (en) * 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
JPH064531B2 (en) * 1990-06-04 1994-01-19 アイセロ化学株式会社 Colon disintegrating hard capsule
JP2773959B2 (en) * 1990-07-10 1998-07-09 信越化学工業株式会社 Colon release solid preparation
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
PL176846B1 (en) * 1993-02-26 1999-08-31 Procter & Gamble Bisacodyl administration form
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4314799C2 (en) * 1993-05-05 1995-04-13 Fein C & E Power tool
ES2163504T5 (en) * 1994-05-06 2008-05-16 Pfizer Inc. DOSAGE FORMS OF CONTROLLED AZITROMYCIN RELEASE.
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system

Also Published As

Publication number Publication date
ATE234079T1 (en) 2003-03-15
JP2001502333A (en) 2001-02-20
CN1233170A (en) 1999-10-27
US5914132A (en) 1999-06-22
JP4276299B2 (en) 2009-06-10
EP0932396B1 (en) 2003-03-12
EP0932396A1 (en) 1999-08-04
CA2268175C (en) 2002-04-23
CN1101675C (en) 2003-02-19
WO1998016206A1 (en) 1998-04-23
DE69719774D1 (en) 2003-04-17
DE69719774T2 (en) 2003-08-21
BR9712292A (en) 1999-08-31

Similar Documents

Publication Publication Date Title
CA2268175A1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CA2268868A1 (en) Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
DE69619668T2 (en) PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE GAROL-SOLUBLE POLYMER COATING FOR ACTIVE SUBSTANCE DELIVERY IN THE COLON
DE69630375D1 (en) PHARMACEUTICAL DOSAGE FORM FOR RELEASE IN THE COLON
US5840332A (en) Gastrointestinal drug delivery system
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
EP1021171B1 (en) Delayed total release gastrointestinal drug delivery system
US5891474A (en) Time-specific controlled release dosage formulations and method of preparing same
CA2181502A1 (en) Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
CA2377916A1 (en) Taste masked pharmaceutical liquid formulations
CA2509976A1 (en) Modified release pharmaceutical composition
CA2271569A1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CA2271560A1 (en) Pharmaceutical dosage form for colonic delivery
NO992350L (en) Pharmaceutical dosage form with multiple enteric polymer coatings for delivery in the large intestine
NO992349L (en) Pharmaceutical surface dosage form for delivery to the colon
BR9612801A (en) Pharmaceutical dosage form with multiple coatings of enteric polymers for colonic supply.
BR9612800A (en) Pharmaceutical dosage form for colonic distribution.
MXPA00003438A (en) Delayed total release gastrointestinal drug delivery system
CA2223014A1 (en) Controlled release formulation having a preformed passageway

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed